Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1

Oncogene

Volumn 31, Issue 44, 2012, Pages 4698-4708

  Fassl, A ^a   Tagscherer, K E ^a   Richter, J ^a   Berriel Diaz, M ^b   Alcantara Llaguno, S R ^c   Campos, B ^d   Kopitz, J ^d   Herold Mende, C ^d   Herzig, S ^b   Schmidt, M H H ^e   Parada, L F ^c   Wiestler, O D ^a   Roth, W ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

apoptosis; EGFR; glioblastoma; Mcl 1; Notch1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GW 280264X; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84869084740     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.615     Document Type: Article

References (50)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776. (Pubitemid 29291335)
2. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
3. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65: 2353-2363. (Pubitemid 40490146)
4. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007; 106: 417-427. (Pubitemid 46354295)
5. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, Zhou P et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem 2008; 307: 101-108. (Pubitemid 350238652)
6. Xu P, Qiu M, Zhang Z, Kang C, Jiang R, Jia Z et al. The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo. J Neurooncol 2010; 97: 41-51.
7. Oishi K, Kamakura S, Isazawa Y, Yoshimatsu T, Kuida K, Nakafuku M et al. Notch promotes survival of neural precursor cells via mechanisms distinct from those regulating neurogenesis. Dev Biol 2004; 276: 172-184. (Pubitemid 39452853)
8. Liu WH, Hsiao HW, Tsou WI, Lai MZ. Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation. EMBO J 2007; 26: 1660-1669.
9. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28: 17-28.
10. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006; 66: 4715-4724.
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401. (Pubitemid 39551674)
12. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021. (Pubitemid 39331011)
13. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-822.
14. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403. (Pubitemid 43668737)
15. Koch P, Opitz T, Steinbeck JA, Ladewig J, Brustle O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc Natl Acad Sci USA 2009; 106: 3225-3230.
16. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-2728.
17. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
18. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 8: 119-130. (Pubitemid 41132741)
19. Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 1999; 181: 393-409. (Pubitemid 29513408)
20. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000; 5: 207-216. (Pubitemid 30628080)
21. van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 2009; 284: 31018-31027.
22. Opferman JT. Unraveling MCL-1 degradation. Cell Death Differ 2006; 13: 1260-1262. (Pubitemid 44057455)
23. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
24. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005; 280: 10491-10500. (Pubitemid 40395908)
25. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107.
26. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21: 749-760. (Pubitemid 43376126)
27. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002; 277: 43730-43734. (Pubitemid 36157790)
28. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313: 144-147. (Pubitemid 15192341)
29. Leu CM, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporineinduced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 2000; 19: 1665-1675. (Pubitemid 30200968)
30. Yoon JH, Werneburg NW, Higuchi H, Canbay AE, Kaufmann SH, Akgul C et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002; 62: 6500-6505. (Pubitemid 35364114)
31. Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 2010; 16: 671-677.
32. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP et al. Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 2008; 29: 918-925. (Pubitemid 351982234)
33. Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res 2010; 70: 5368-5378.
34. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399. (Pubitemid 44711953)
35. Henson ES, Gibson EM, Villanueva J, Bristow NA, Haney N, Gibson SB. Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem 2003; 89: 1177-1192. (Pubitemid 36959385)
36. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006; 281: 10153-10163. (Pubitemid 43864551)
37. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al. Apoptosisbased treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27: 6646-6656.
38. Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit downregulation of caspase-8 by promoter methylation. Acta Neuropathol 2009; 117: 445-456.
39. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710. (Pubitemid 350070717)
40. Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harb Symp Quant Biol 2008; 73: 367-375.
41. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28: 5-16.
42. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating Ncadherin expression. Cancer Res 2006; 66: 4182-4190.
43. Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci 2008; 28: 6068-6078.
44. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-814. (Pubitemid 27106152)
45. Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH et al. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem 2009; 284: 30039-30048.
46. Schultz A, Jonsson JI, Larsson C. The regulatory domain of protein kinase Ctheta localises to the Golgi complex and induces apoptosis in neuroblastoma and Jurkat cells. Cell Death Differ 2003; 10: 662-675. (Pubitemid 36675728)
47. Chen J, Kesari S, Rooney C, Strack PR, Shen H, Wu L et al. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010; 1: 822-835.
48. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006; 118: 2182-2189.
49. Schmidt MH, Bicker F, Nikolic I, Meister J, Babuke T, Picuric S et al. Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal. Nat Cell Biol 2009; 11: 873-880.
50. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.